Bayer May Not Launch In Innovation-Unfriendly European Markets

Concerns Growing Over Current Environment

01 Mar 2023

The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.

With a number of countries in Europe opting for policies perceived by the pharmaceutical industry as harmful to innovation, Bayer AG's pharma chief has told Scrip that there could come a time when the firm opts not to launch new medicines in some parts of the continent.

Speaking as the German group posted a solid set of financials for the fourth quarter 2022, Stefan Oelrich said that...